Human placenta-derived mesenchymal stem cells suppress T cell proliferation and support the culture expansion of cord blood CD34+ cells: A comparison with human bone marrow-derived mesenchymal stem cells
Human placenta-derived mesenchymal stem cells suppress T cell proliferation and support the culture expansion of cord blood CD34+ cells: A comparison with human bone marrow-derived mesenchymal stem cells
复制标题
人胎盘来源的间充质干细胞抑制 T 细胞增殖并支持脐带血 CD34+ 细胞的培养扩增：与人骨髓来源的间充质干细胞的比较
DOI：
10.1016/j.tice.2012.09.002
复制
发表时间：
2013-02-01
期刊：
影响因子：
2.6
通讯作者：
Lin, Yanhua
中科院分区：
文献类型：
--
作者：
Luan, Xiying;Li, Guangyun;Lin, Yanhua
人胎盘来源的间充质干细胞（hPMSC）已被证明具有针对T细胞的免疫抑制作用，并支持来自脐带血（UCB）的造血干/祖细胞（HSPC）的扩增。然而，与人骨髓间充质干细胞（hBMSCs）相比，hPMSCs的特性尚未完全了解。在这里，我们表明，hPMSCs有类似的调节作用，对T细胞的活化，增殖和细胞因子分泌的hBMSCs和证明，PDL 1和B7 H4，负共刺激分子，参与了T细胞的免疫抑制活性的hPMSCs和hBMSCs，分别。与hBMSCs相比，hPMSCs能有效促进脐血CD 34（+）细胞的扩增。此外，hPMSC维持了CD 34（+）细胞中粘附分子（CD 11 a、CD 44和CD 49 e）的表达。观察到hPMSCs和hBMSCs对CD 34（+）细胞趋化性和细胞因子（如SDF-1 α、IL-6和SCF）产生的类似作用。因此，hPMSCs可能是一种理想的hBMSCs替代来源，可用于基础研究和临床应用，这对进一步探索hPMSCs的潜在临床应用具有重要意义。(C)2012爱思唯尔有限公司保留所有权利。
Human placenta-derived mesenchymal stem cells (hPMSCs) have been shown to possess immunosuppressive effects against T cells and support the expansion of hematopoietic stem/progenitor cells (HSPCs) from umbilical cord blood (UCB). However, the characteristics of hPMSCs compared with human bone marrow-derived mesenchymal stem cells (hBMSCs) are not fully understood. Here, we show that hPMSCs have similar regulatory effects on T cell activation, proliferation and cytokine secretion as hBMSCs and demonstrate that PDL1 and B7H4, negative co-stimulatory molecules, are involved in the T cell immunosuppressive activities of hPMSCs and hBMSCs, respectively. hPMSCs efficiently enhanced the expansion of CD34(+) cells from UCB compared with hBMSCs. Furthermore, hPMSCs maintained the expression of adhesion molecules (CD11a, CD44 and CD49e) in CD34(+) cells. Similar effects were observed for both hPMSCs and hBMSCs on CD34(+) cell chemotaxis and cytokine production, such as SDF-1 alpha, IL-6 and SCF. Therefore, hPMSCs may be an ideal alternative source of hBMSCs for basic research and clinical applications, which may be significant in future efforts to explore the potential clinical utility of hPMSCs. (C) 2012 Elsevier Ltd. All rights reserved.